Q32 Bio Inc.

QTTB Healthcare Biotechnology

Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million. In the quarter to June 2026, EPS grew 43.6%, free cash flow grew 71.1% and total debt fell 35.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.52 0.25 −3.22%
Market cap
$231.3M
P/E
2.5×
Fwd P/E
−7.2×
Dividend yield
—
F-score
n/a
Altman Z
−0.78
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
50.81 55.05 57.20 109.65
Total non-current assets
6.97 6.73 6.47 6.22
Total Assets
57.78 61.78 63.68 115.87
Total current liabilities
11.11 11.35 10.67 5.40
Total non-current liabilities
65.12 8.42 6.69 4.56
Total liabilities
76.23 19.76 17.36 9.96
Common Equity (Total)
(18.45) 42.01 46.31 105.91
Shareholders Equity (Total)
(18.45) 42.01 46.31 105.91
Total Debt
11.23 9.71 8.18 —

Show all line items

In millions of $ except per-share values · columns are period end dates